Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Study of the Efficacy and Safety of SYNB1618 and SYNB1934 in Patients With Phenylketonuria (SynPheny-1)

Next Previous
X
Search
Trial Profile

An Open-label Study of the Efficacy and Safety of SYNB1618 and SYNB1934 in Patients With Phenylketonuria (SynPheny-1)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Labafenogene marselecobac (Primary) ; SYNB-1618 (Primary)
  • Indications Phenylketonuria
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SynPheny-1
  • Sponsors Synlogic

    • Most Recent Events

    • 20 Mar 2023 Primary endpoint has been met. (Changes from baseline in labeled Phe (D5-Phe) in plasma), according to an Synlogic media release.
    • 20 Mar 2023 According to an Synlogic media release, data from this study were presented at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting, Dr. Jerry Vockley.
    • 07 Mar 2023 According to Synlogic media release, company announced that it will present a podium presentation of poster at the Society of Inherited Metabolic Disorders (SIMDD) 44th Annual Meeting in Salt Lake City, Utah on 19th March 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top